Results 31 to 40 of about 24,654 (177)
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. [PDF]
Philadelphia chromosome (Ph)/BCR/ABL-positive acute lymphoblastic leukemia (ALL) is the most common genetic abnormality associated with adult ALL and has been shown to confer the worst prognosis to both children and adults.[1][1],[2][2] Approximately 3%–5% children and 25%–40% adults with ...
Leoni V, Biondi A.
europepmc +5 more sources
DNA vaccination against bcr-abl-positive cells in mice
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system.
Vincent, Lucansky +4 more
openaire +3 more sources
Imatinib spells BAD news for Bcr/abl-positive leukemias [PDF]
One of the medical success stories of the past decade has been the development of new agents to treat chronic myelogenous leukemia (CML). Building on earlier studies that identified the t(9;22) chromosomal translocation in CML, cloned the BCR/ABL fusion gene, and demonstrated the ability of the resulting kinase to transform cells, investigators ...
openaire +2 more sources
Background Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Mian Afsar +8 more
doaj +1 more source
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac +16 more
wiley +1 more source
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias [PDF]
Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl(+)) leukemias. Although they are known to promote caspase-mediated apoptosis, it remains unclear whether caspase-independent cell death-inducing mechanisms are also triggered.
Y, Kamitsuji +16 more
openaire +2 more sources
Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng +6 more
wiley +1 more source
Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias
Abstract Learning Objectives After taking all of the CME courses in this supplement the reader will be able to: Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS).
openaire +2 more sources
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source
Background: BCR-ABL translocation is the most common genetic abnormality associated with adult Acute Lymphoblastic Leukaemia (ALL) with poor outcome. Objective: The aim of the study was to determine the association of myeloid aberrant antigens and the ...
Md. Shafiul Azam +5 more
doaj +1 more source

